SHSteffen Hauptmann

Steffen Hauptmann

*This is an algorithmically generated author record based on publicly available information.

Steffen Hauptmann has a total of 49 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Primary angiosarcoma of the ovary with prominent fibrosis of the ovarian stroma. Case report of an 81-year old patient

    by Hans Bösmüller, Christine Gruber, Sophie Haitchi-Petnehazy, Dietmar Wagner, Gerald Webersinke, Steffen Hauptmann

    Primary angiosarcoma of the ovary (AS) is a rare entity with only 31 reported cases. The majority are pure angiosarcomas, the remainder are associated either with teratomas or conventional epithelial tumors. More than 50% of ovarian AS are disseminated at the time of diagnosis, the minority is detected in stage I. The prognosis of ovarian angiosarcoma in general is poor. Most reports refer to younger individuals, aged from 7 to 46 years, and only 2 case reports could be found for patients older than 64 years. Here we present a very unusual case of angiosarcoma in a 81-year-old patient.


  • Open Access

    Expression of survivin detected by immunohistochemistry in the cytoplasm and in the nucleus is associated with prognosis of leiomyosarcoma and synovial sarcoma patients

    by Helge Taubert, Chris Heidenreich, Hans-Jürgen Holzhausen, Antje Schulz, Matthias Bache, Matthias Kappler, Alexander W Eckert, Peter Würl, Ingo Melcher, Kathrin Hauptmann, et al.

    Survivin, a member of the inhibitor of apoptosis-protein family suppresses apoptosis and regulates cell division. It is strongly overexpressed in the vast majority of cancers. We were interested if survivin detected by immunohistochemistry has prognostic relevance especially for patients of the two soft tissue sarcoma entities leiomyosarcoma and synovial sarcoma.


  • Open Access

    Reliability and validity of needle biopsy evaluation of breast-abnormalities using the B-categorization – design and objectives of the Diagnosis Optimisation Study (DIOS)

    by Alexander Kluttig, Pietro Trocchi, Anke Heinig, Hans-Juergen Holzhausen, Christiane Taege, Steffen Hauptmann, Werner Boecker, Thomas Decker, Thomas Loening, Andrea Schmidt-Pokrzywniak, et al.

    The planned nationwide implementation of mammography screening 2007 in Germany will increase the occurrence of mammographically detected breast abnormalities. These abnormalities are normally evaluated by minimal invasive core biopsy. To minimize false positive and false negative histological findings, quality assurance of the pathological evaluation of the biopsies is essential. Various guidelines for quality assurance in breast cancer diagnosis recommend applying the B-classification for histopathological categorization. However, to date there are only few studies that reported results about reliability and validity of B-classification. Therefore, objectives of our study are to determine the inter- and intraobserver variability (reliability study) and construct and predictive validity (validity study) of core biopsy evaluation of breast abnormalities. This paper describes the design and objectives of the DIOS Study.


  • Expression of the RNA-binding protein IMP1 correlates with poor prognosis in ovarian carcinoma

    by M Köbel, D Weidensdorfer, C Reinke, M Lederer, W D Schmitt, K Zeng, C Thomssen, S Hauptmann, S Hüttelmaier

    The IMP (IGFII mRNA-binding protein) family comprises a group of three RNA-binding proteins involved in the regulation of cytoplasmic mRNA-fate. Recent studies identified IMP proteins as oncofetal factors in various neoplasias, but knowledge of a potential role in ovarian carcinomas is still lacking. The immunohistochemical analysis of 107 ovarian carcinomas, 30 serous borderline tumors of the ovary and five normal ovaries revealed de novo synthesis of IMP1 in 69% of ovarian carcinomas. Elevated IMP1 expression was observed preferentially in high-grade and high-stage cases and was a significant prognostic indicator for reduced recurrence-free and overall survival. Phenotypic studies in ovarian carcinoma-derived ES-2 cells demonstrated that IMP1 knockdown affects proliferation and cell survival. Reduced proliferation was associated with decreased c-myc mRNA half-life, suggesting IMP1 as an oncogenic factor that is involved in promoting elevated proliferation by stabilizing the c-myc mRNA in ovarian carcinoma cells.


  • Differenzialdiagnostik ovarieller Metastasen

    by S. Hauptmann

    Ovarian metastases comprise 7-10% of all malignant ovarian tumors. The detection of ovarian metastases is difficult because primary ovarian tumors are a morphologically very heterogeneous group, and metastases can simulate an primary ovarian tumor perfectly. A correct diagnosis, however, is most important in order to avoid an unnecessary and ineffective chemotherapy. Therefore, every morphologically unusual ovarian tumor should raise doubts. In addition, mucinous and endometrioid tumors may also be metastatic in nature. Immunohistochemistry, as well as knowledge on the patient's history, will clarify most of the suspicious cases.


  • Open Access

    Genetic dissection of apoptosis and cell cycle control in response of colorectal cancer treated with preoperative radiochemotherapy

    by Isrid Sturm, Beate Rau, Peter M Schlag, Peter Wust, Bert Hildebrandt, Hanno Riess, Steffen Hauptmann, Bernd Dörken, Peter T Daniel

    Background: In previous analyses we identified therapy-induced upregulation of the CDK inhibitor p21CIP/WAF-1 and consequently decreased tumor cell proliferation or loss of Bax as adverse factors for survival in rectal cancer treated with radiochemotherapy. Here, we address the individual role of p53 and its transcriptional targets, p21CIP/WAF-1 and Bax, on apoptosis induced by individual components of multimodal anticancer therapy, i.e. 5-fluorouracil (5-FU), ionising γ-radiation (IR) and heat shock/hyperthermia. Methods: We analysed tumor samples 66 patients with rectal carcinoma treated by a neoadjuvant approach with radiochemotherapy ± heat shock/hyperthermia for the expression and mutation of p53 and the expression of p21CIP/WAF-1 and Bax. These data were correlated with the tumor response. The functional relevance of p53, p21CIP/WAF-1 and Bax was investigated in isogeneic HCT116 cell mutants treated with 5-FU, IR and heat shock. Results: Rectal carcinoma patients who received an optimal heat shock treatment showed a response that correlated well with Bax expression (p = 0.018). Local tumor response in the whole cohort was linked to expression of p21CIP/WAF-1 (p < 0.05), but not p53 expression or mutation. This dichotomy of p53 pathway components regulating response to therapy was confirmed in vitro. In isogeneic HCT116 cell mutants, loss of Bax but not p53 or p21CIP/WAF-1 resulted in resistance against heat shock. In contrast, loss of p21CIP/WAF-1 or, to a lesser extent, p53 sensitized predominantly for 5-FU and IR. Conclusion: These data establish a different impact of p53 pathway components on treatment responses. While chemotherapy and IR depend primarily on cell cycle control and p21, heat shock depends primarily on Bax. In contrast, p53 status poorly correlates with response. These analyses therefore provide a rational approach for dissecting the mode of action of single treatment modalities that may be employed to circumvent clinically relevant resistance mechanisms in rectal cancer.


    • 17 August 2005
      • Vol. 25  (5) , 3431-6

    Glucose transporter GLUT1 in colorectal adenocarcinoma cell lines is inversely correlated with tumour cell proliferation.

    by Steffen Hauptmann, Verena Grünewald, Denise Molls, Wolfgang D Schmitt, Martin Köbel, Karen Kriese, Annette Schürmann

    The high glucose consumption of tumour cells has been well known since Warburg's investigations. Nevertheless, the reason for this phenomenon is still a matter of speculation. Glucose uptake of tumour cells is mainly mediated by GLUT1. In this study, the question of whether glucose uptake as well as expression of GLUT1 are both related to tumour cell proliferation was addressed. Three kinetically different cell lines of colorectal adenocarcinomas (HRT-18, HT29 and CX-2) were used for the experiments. All the cell lines expressed GLUT1 at a high level, being mainly localized within the cell membrane and the endoplasmic reticulum. Surprisingly, the highest expression of GLUT1 was found in the most slowly proliferating cell line, CX-2. Moreover, induction of cell cycle arrest increased both GLUT1 expression and glucose consumption, as well as global protein synthesis. These data suggest that the protein synthesis of tumour cells is much more glucose-consuming than proliferation and that both processes are inversely related.


    • 1 January 2005
      • Vol. 89, 92-100

    [Prognostic factors in ovarian carcinoma].

    by S Hauptmann, M Köbel

    Ovarian carcinoma is the most lethal gynaecological malignancy in the western world with a five year survival rate of appr. 35 %. Unfortunately, most patients present with advanced disease, and their standard treatment is maximal surgical debulking and chemotherapy consisting of carboplatin and taxol. The most important prognostic factor in these patients is residual tumor after primary surgery. In patients with ovarian carcinoma confined to the ovary prognostic factors are important. Currently, high-grade and clear cell histology are regarded as worse prognostic factors, and these patients receive chemotherapy. Studies on prognostic factors in ovarian carcinomas are usually hampered by a low number of patients, and the lack of essential data (residual tumor, chemotherapy, and histological type), making meta-analyses impossible. For the future, prospective studies on putative prognostic factors are necessary. Moreover, for patients with advanced disease the evaluation of predictive factors (chemoresistance) as well as studies on the importance of the inflammatory background present in the tumor-seeded peritoneal cavity will get important.